Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Figure 3

Heat plot for the analysis of different IO combinations. IO: immunotherapy; OS: overall survival; PFS: progression-free survival; CRR: complete response rate; ORR: objective response rate; DCR: disease control rate; TRAEs: treatment-related adverse events; irAEs: immune-related adverse events. camre: camrelizumab; nivo: nivolumab; sinti: sintilimab; tori: toripalimab; tisle: tislelizumab; pembro: pembrolizumab; chemo: chemotherapy.